6-1 Journal Rejecting and Failing to Reject the Null Hypothesis

docx

School

Southern New Hampshire University *

*We aren’t endorsed by this school

Course

BUS 210

Subject

Statistics

Date

Jan 9, 2024

Type

docx

Pages

3

Uploaded by ColonelDonkey3482

Report
6-1 Journal: Rejecting and Failing to Reject the Null Hypothesis What is the difference between failing to reject the null hypothesis and having evidence to support the alternative hypothesis? Failing to Reject the Null Hypothesis occurs when the statistical test's p-value is higher than the alpha, the level at which a difference is considered significant. Researchers fail to reject the null hypothesis when the p-value exceeds the predetermined significance level (alpha), which is typically set at 0.05 or 0.01. This indicates that not enough statistical data exists to draw a conclusion about the existence of a significant difference or effect. Having Evidence to Support the Alternative Hypothesis occurs whenever the p-value is below the alpha, the predetermined level of significance. This outcome suggests that the data provides sufficient statistical evidence to reject the null hypothesis in favor of the alternative hypothesis. It is crucial to understand that "failing to reject" simply indicates that there is insufficient evidence to support the alternative hypothesis; it does not demonstrate that the null hypothesis is true. Conversely, "having evidence to support the alternative hypothesis" indicates that the data provides support for the claim researchers are investigating. I work as a research assistant, conducting clinical trials for new chemotherapy treatment drugs for cancer patients with specific cancers. The null hypothesis assumes that the new chemotherapy drug is not more effective than the existing standard of care drug. The alternative hypothesis, which suggests that the new chemotherapy drug is more effective than the standard of care drug. During the clinical trials, we evaluate to see if the new chemotherapy drug is more effective than standard of care chemotherapy drug. We put our patient also known as “subjects” (due to PHI) into a database to be randomized to see if the patient is eligible for the new chemotherapy drug or ineligible and will receive the placebo drug. This is the predetermined threshold set at 0.05 in my case. It represents the probability of making a Type I error rejecting
the null hypothesis when it is true. A common choice in scientific research is α = 0.05. This is a statistical measure that quantifies the strength of evidence against the null hypothesis. If the p- value is less than or equal to α 0.05, reject the null hypothesis, suggesting that there is enough evidence to support the alternative hypothesis. If the p-value is less than α, I conclude that the new chemotherapy drug is statistically significantly more effective than the existing treatment. This suggests that there is enough empirical evidence to consider the new drug for further development and clinical use. On the other hand, if the p-value is greater than α, it’d fail to reject the null hypothesis, indicating that there's not enough statistical evidence to claim that the new drug is more effective. Evidence to support the alternative hypothesis means that the data and statistical analysis have provided convincing evidence that the treatment or effect that is being investigated is real and not due to random chance. It is a key outcome in hypothesis testing and scientific research, as it informs decision-making and the adoption of new treatments or ideas.
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
  • Access to all documents
  • Unlimited textbook solutions
  • 24/7 expert homework help